Molecular biomarkers will be central to the rapidly-developing field of personalized medicine for cancer; however, there are numerous challenges to overcome, particularly in the complicated area of solid tumor-based cancers.  Using our leadership and experience in the areas of cytopathology, molecular pathology, molecular diagnostics, bioengineering and cancer biomarker research, BioMarker Strategies is developing the SnapPath ^(TM) automated tumor cell processing and sample preparation system to minimize pre-analytical variability in the analysis of solid human tumor cells, while simultaneously maximizing the molecular diagnostic potential of these cells. The SnapPath ^(TM) system will advance the field of personalized medicine for cancer by preserving the biological integrity of an individual's tumor cells.

If you are interested in learning more about BioMarker Strategies, including our investor issues, media center, or employment opportunities, please contact us.